-
Mashup Score: 5
Author links open overlay panel, , , , , , , , , , , , , , , , , , ,
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1The Room Where It Happens: Addressing Diversity, Equity, and Inclusion in NCTN Clinical Trial Leadership - 11 month(s) ago
Abstract. Many multicenter randomized clinical trials in oncology are conducted through the National Clinical Trials Network (NCTN), an organization consisting
Source: OUP AcademicCategories: Hem/Oncs, Latest HeadlinesTweet-
Very proud to be a part of the #NCTN Task Force on Diversity in GI Onology. Thank you Rebecca Snyder for leading this discussion on #DEI in the NCTN. Room Where It Happens: Addressing Diversity, Equity, and Inclusion in NCTN Clinical Trial Leadership https://t.co/qwYmxiTxoy
-
-
Mashup Score: 0You Don’t Have to Be in Your 20s to Get HPV — Here’s What Older Adults Need to Know - 12 month(s) ago
And what to do if you have it already.
Source: Katie Couric MediaCategories: Hem/Oncs, Latest HeadlinesTweet-
Thank you @katiecouric for spreading the word about #HPV -related cancers and #vaccines. @HPVAnalCancer @HPVAlliance Can Older People Get HPV or the Vaccine? | KCM https://t.co/yTJWazQTis
-
-
Mashup Score: 9Fiducial Markers Allow Accurate and Reproducible Delivery of Liver Stereotactic Body Radiation Therapy - 12 month(s) ago
Fiducial markers are utilized for image guided radiotherapy (IGRT) alignment during the delivery of liver stereotactic body radiosurgery (SBRT). There are limited data demonstrating the impact of matching fiducials on the accuracy of liver SBRT. This study quantifies the benefit of fiducial-based alignment and improvements in inter-observer reliability. Nineteen patients with 24 liver lesions…
Source: MDPICategories: Hem/Oncs, Latest HeadlinesTweet-
🔖 Our latest research, led by @mmoskalenkomd is out in @CurrentOncology! We found that using fiducial markers in liver SBRT can aid in achieving more accurate and consistent treatment setups. Congrats to the whole team. Read the full study here: https://t.co/Dje4RdFYDx https://t.co/yY8tgXX0Cd
-
-
Mashup Score: 7TCI Connections April 2023 - 1 year(s) ago
News from The Tisch Cancer Institute {View as Webpage} April 2023 Tisch Cancer Hospital Leadership Cardinale B. Smith, MD, PhD, has been appointed Chief Medical Officer for the Tisch Cancer Hospital a
Categories: Hem/Oncs, Latest HeadlinesTweet-
🏆 Excited to share I've been awarded an R50 from @theNCI to support my work in cancer clinical trials at @TischCancer. Grateful for this opportunity to expand access to NCI-sponsored clinical trials to our patients: https://t.co/m3GVGODHsE https://t.co/DpYDn8XkLK
-
-
Mashup Score: 3At Moonshot forum, expert in early-onset colorectal cancer calls for greater trial funding - 1 year(s) ago
Cathy Eng, MD, FACP, FASCO, joined a panel of experts at the White House Cancer Moonshot Colorectal Cancer Forum in highlighting the need for greater patient participation in and funding for cancer clinical trials.Eng, the David H. Johnson professor of surgical and medical oncology at Vanderbilt University, described the panel discussion last month as very productive. Other participants
Source: www.healio.comCategories: Hem/Oncs, Latest HeadlinesTweet-
✨Thrilled to see my esteemed colleague & co-chair of @theNCI's GI Steering Committee, Dr. @CathyEngMD, featured in a recent interview about the need for greater patient participation & funding for cancer clinical trials. Incredible work! https://t.co/PiTtrc6qi2
-
-
Mashup Score: 0
11 likes, 2 comments – Mount Sinai Radiation Oncology (@mountsinairadonc) on Instagram: “Last week, our Department of Radiation Oncology at Mount Sinai met for our fourth Research Retrea…”
Source: InstagramCategories: Hem/Oncs, Latest HeadlinesTweet-
https://t.co/dG72Nxo0ao
-
-
Mashup Score: 5Phase 1 Dose Escalation Study of SBRT Using 3 Fractions for Locally Advanced Pancreatic Cancer - 1 year(s) ago
The optimal dose and fractionation of stereotactic body radiation therapy (SBRT) for locally advanced pancreatic cancer (LAPC) have not been defined. Single-fraction SBRT was associated with more gastrointestinal toxicity, so 5-fraction regimens have become more commonly employed. We aimed to determine the safety and maximally tolerated dose of 3-fraction SBRT for LAPC.
Categories: Hem/Oncs, Latest HeadlinesTweet-
In our newest paper, we explored a 3-fraction regimen of stereotactic body radiotherapy (SBRT) for locally advanced pancreatic cancer. We found no dose-limiting toxicities & maintenance of patients' quality of life. Learn more: https://t.co/YKgnQTlLTb https://t.co/3EmXX7IAJW
-
-
Mashup Score: 4What You Need To Know About Pancreatic Cancer Treatment - 1 year(s) ago
Dr. Karyn Goodman explains the signs and symptoms of pancreatic cancer and why patients should go to the Pancreatic Cancer Multidisciplinary Team after a pan…
Source: YouTubeCategories: Hem/Oncs, Latest HeadlinesTweet-
We're celebrating 1 year of the Center of Excellence for #PancreaticCancer at @MountSinaiNYC 🌟 We are proud to have really grown our one-stop multidisciplinary approach for comprehensive care. 📺 Watch: https://t.co/jbhoGfKoRw 🔗 Clinic info: https://t.co/HXXwSgtxpw https://t.co/HYKoeiKXbq
-
-
Mashup Score: 14Gender Differences in the Research Productivity of Radiation Oncology Resident Graduates in the United States: 2015 to 2019 - 1 year(s) ago
It is well-documented that gender disparities exist in academic radiation oncology departments. The purpose of this study was to analyze gender differences in research productivity during residency among recent graduates of radiation oncology training programs in the United States (US).
Source: Advances in Radiation OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Before #WomensHistoryMonth ends, take a look at our work showing gender disparities in research productivity amongst radiation oncology residents, which disproportionately impact women’s careers. Let’s work to close this gap with support & mentorship! https://t.co/SjReNEzbsd https://t.co/kCdLYSnFFU
-
Great to be part of this novel approach for patients with pancreatic cancer. @MPishvaian - look forward to the presentation at #ESMO23. #PancreaticCancer LBA-1 The Phase III Study: Targeted intra-arterial gemcitabine vs. con... https://t.co/L2ShXoS4WZ